Fennec Pharmaceuticals In...

5.64
-0.30 (-5.05%)
At close: Apr 03, 2025, 3:59 PM
5.85
3.68%
After-hours: Apr 03, 2025, 07:16 PM EDT

Fennec Pharmaceuticals Statistics

Share Statistics

Fennec Pharmaceuticals has 27.59M shares outstanding. The number of shares has increased by 1% in one year.

Shares Outstanding 27.59M
Shares Change (YoY) 1%
Shares Change (QoQ) 0.61%
Owned by Institutions (%) 58.63%
Shares Floating 23.05M
Failed to Deliver (FTD) Shares 871
FTD / Avg. Volume 1.13%

Short Selling Information

The latest short interest is 2M, so 7.28% of the outstanding shares have been sold short.

Short Interest 2M
Short % of Shares Out 7.28%
Short % of Float 8.72%
Short Ratio (days to cover) 25.61

Valuation Ratios

The PE ratio is -395.64 and the forward PE ratio is -41.27. Fennec Pharmaceuticals's PEG ratio is 4.06.

PE Ratio -395.64
Forward PE -41.27
PS Ratio 3.63
Forward PS 1
PB Ratio -31.33
P/FCF Ratio 6.39
PEG Ratio 4.06
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Fennec Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.38, with a Debt / Equity ratio of -3.51.

Current Ratio 6.38
Quick Ratio 6.22
Debt / Equity -3.51
Debt / EBITDA 5.37
Debt / FCF 0.72
Interest Coverage 0.63

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $1.49M
Profits Per Employee $-13.63K
Employee Count 32
Asset Turnover 1.06
Inventory Turnover 3

Taxes

Income Tax 365K
Effective Tax Rate -514.08%

Stock Price Statistics

The stock price has increased by -45.03% in the last 52 weeks. The beta is 0.36, so Fennec Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.36
52-Week Price Change -45.03%
50-Day Moving Average 6.52
200-Day Moving Average 5.79
Relative Strength Index (RSI) 41.01
Average Volume (20 Days) 77.01K

Income Statement

In the last 12 months, Fennec Pharmaceuticals had revenue of 47.54M and earned -436K in profits. Earnings per share was -0.02.

Revenue 47.54M
Gross Profit 44.35M
Operating Income 2.57M
Net Income -436K
EBITDA 3.6M
EBIT 2.57M
Earnings Per Share (EPS) -0.02
Full Income Statement

Balance Sheet

The company has 26.63M in cash and 19.34M in debt, giving a net cash position of 7.29M.

Cash & Cash Equivalents 26.63M
Total Debt 19.34M
Net Cash 7.29M
Retained Earnings -219.68M
Total Assets 44.95M
Working Capital 37.47M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 26.98M and capital expenditures 0, giving a free cash flow of 26.98M.

Operating Cash Flow 26.98M
Capital Expenditures 0
Free Cash Flow 26.98M
FCF Per Share 0.99
Full Cash Flow Statement

Margins

Gross margin is 93.3%, with operating and profit margins of 5.4% and -0.92%.

Gross Margin 93.3%
Operating Margin 5.4%
Pretax Margin -0.15%
Profit Margin -0.92%
EBITDA Margin 7.57%
EBIT Margin 5.4%
FCF Margin 56.75%

Dividends & Yields

FENC does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for FENC is $14, which is 136.5% higher than the current price. The consensus rating is "Buy".

Price Target $14
Price Target Difference 136.5%
Analyst Consensus Buy
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Sep 9, 2014. It was a backward split with a ratio of 1:3.

Last Split Date Sep 9, 2014
Split Type backward
Split Ratio 1:3

Scores

Altman Z-Score -2.69
Piotroski F-Score 4